No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
209 |
4. Check minimum number of eventsNone |
209 |
5. Include endpointsNone |
209 |
6. Filter based on genotype QC (FinnGen only) |
189 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF9
- Name in latin
- Carcinoma in situ labii (oris)
Similar endpoints
↥List of similar endpoints to
Chromophobe cell carcinoma of kidney
based on the number of shared cases.
Similar with more cases:
- Renal cell carcinoma of kidney
- Malignant neoplasm of kidney, except renal pelvis
- Malignant neoplasm of urinary organs
- Malignant neoplasm of kidney, except renal pelvis, including Hilmo
- Malignant neoplasm of urinary organs, including Hilmo
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 189 | 72 | 117 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 68.09 | 65.72 | 69.54 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 197
- Matched controls
- 1970
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
809.4
307.7
168
14
8317/3-C64.9
ICD-O-3
Renal cell carcinoma, chromophobe type of kidney, NOS
+∞
285.2
197
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
258.8
187
*
JN4AD
NOMESCO Finland
Body CT examination
21.6
92.0
82
63
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
20.8
65.7
55
36
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
+∞
61.8
56
*
B01AB10
ATC
tinzaparin; parenteral
13.6
61.7
70
77
WX302
NOMESCO Finland
Thoracal epidural anesthesy
28.5
57.8
41
18
KAD01
NOMESCO Finland
Percutaneous endoscopic partial nephrectomy
624.6
50.8
48
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
119.3
44.0
46
5
KAD00
NOMESCO Finland
Partial nephrectomy
241.5
39.4
39
*
JN4BD
NOMESCO Finland
Extensive body CT
12.6
37.3
40
39
KAC10
NOMESCO Finland
Total nephrectomy with capsule
+∞
34.4
32
*
WX408
NOMESCO Finland
General anesthesy, balanced
5.8
33.3
96
278
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.9
33.0
64
128
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
32.2
30
*
TPH07
NOMESCO Finland
Cathetrisation of artery
6.2
30.0
65
144
130
Kela drug reimbursment
Malignant tumour
+∞
27.8
26
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
12.4
27.5
29
27
JN4CD
NOMESCO Finland
Very extensive body CT
36.4
24.6
31
10
WX402
NOMESCO Finland
General anaesthesia
4.4
21.0
73
233
KA1AE
NOMESCO Finland
Kidney ultrasound examination
20.2
20.8
31
18
U75
ICPC
Malignant neoplasm of kidney
+∞
20.1
19
*
B01AB05
ATC
enoxaparin; parenteral
3.9
19.9
99
405
H02AB02
ATC
dexamethasone; systemic
49.2
18.7
22
5
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
18.0
17
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
16.9
16
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.6
16.8
47
125
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
15.8
135
748
Z51.5
ICD-10 Finland
Palliative care
7.0
15.4
25
40
WZC30
NOMESCO Finland
Teaching
4.2
15.3
49
144
R4110
NOMESCO Finland
Physiotherapy
3.3
14.4
81
345
ZXE10
NOMESCO Finland
More than one and less than three hours
3.0
12.7
91
439
N02AX02
ATC
tramadol; systemic, rectal
2.9
12.0
114
635
197
Kela drug reimbursment
Sunitinib
+∞
11.6
11
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
11.6
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
46.1
11.1
13
*
116
Kela drug reimbursment
Prostate cancer
+∞
10.5
10
*
JN3AD
NOMESCO Finland
Abdominal CT examination
3.5
10.3
40
133
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.2
10.2
48
180
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
42.4
10.1
12
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
42.4
10.1
12
*
N02BE01
ATC
paracetamol; systemic, rectal
6.7
9.7
190
1581
WF002
NOMESCO Finland
Radical radiotherapy
104.9
9.5
10
*
Y77
ICPC
Malignant neoplasm prostate
+∞
9.4
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.4
9
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
9.4
9
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.4
9.3
19
38
S18
ICPC
Laceration/cut
2.5
8.9
117
728
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.0
8.9
27
75
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.8
8.9
30
90
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
10.8
8.7
16
16
KAC00
NOMESCO Finland
Nephrectomy
+∞
8.4
8
*
KA3LT
NOMESCO Finland
Njurlesion coagulation
+∞
8.4
8
*
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
8.3
69
346
ZXC96
NOMESCO Finland
Robot assisted procedure
46.9
7.8
9
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
7.3
7.5
17
25
L02AE02
ATC
leuprorelin; implant, parenteral
83.1
7.5
8
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
11.5
7.4
13
12
ZXA00
NOMESCO Finland
Right side
2.4
7.4
68
355
322
Kela drug reimbursment
Sunitinib
+∞
7.3
7
*
L01XE04
ATC
[U] sunitinib
+∞
7.3
7
*
U14
ICPC
Kidney symptom/complaint
9.3
7.2
14
16
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.6
7.1
25
77
XKD00
NOMESCO Finland
Uroflowmetry
2.7
7.1
46
203
SPAT1153
SPAT
Removal of sutures
2.3
6.9
76
426
N19
ICD-10 Finland
Unspecified kidney failure
4.3
6.8
18
45
A04AA01
ATC
ondansetron; systemic, rectal
7.3
6.7
15
22
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.1
6.5
7
*
Z31.5
ICD-10 Finland
Genetic counselling
6.7
6.3
15
24
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
+∞
6.3
6
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
1502
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
3012
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
+∞
6.3
6
*
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
4.4
6.2
16
39
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
165
735
8.66
35.33
3.0
2.5
—
—
estimate
—
0
0
158
786
6.10
26.48
11.1
6.0
1.19
1.20
mmol/l
1.17
151
719
135
638
4.55
22.90
4.9
2.9
—
—
—
0
0
75
243
4.37
21.21
7.5
7.6
-0.25
1.34
mmol/l
3.29
66
208
75
246
4.31
20.82
7.6
7.5
5.37
5.21
kpa
0.88
75
239
79
273
4.16
20.35
8.0
6.6
104.92
104.13
mmol/l
0.76
79
273
143
761
4.21
19.21
7.5
3.7
35.47
35.72
g/l
0.20
137
712
156
884
4.67
19.11
12.3
6.2
1.20
1.21
mmol/l
0.56
133
780
109
501
3.63
17.92
4.6
2.8
0.36
0.37
e6/l
0.02
80
358
117
571
3.58
17.33
5.0
3.0
292.33
153.47
e6/l
0.19
87
428
81
314
3.68
17.21
4.2
2.6
0.49
0.87
e6/l
1.43
43
161
39
90
5.16
16.55
3.1
1.4
38.62
2.48
ug/l
0.52
28
72
92
400
3.44
16.14
2.6
2.1
—
—
—
0
0
74
289
3.50
15.27
4.2
2.8
0.91
1.64
e6/l
0.47
36
136
187
1316
9.29
15.20
12.7
5.9
80.47
77.83
u/l
0.32
181
1229
151
912
3.81
15.09
11.3
6.8
4.48
4.35
e9/l
0.21
126
802
100
551
2.65
10.30
5.5
1.9
2.38
2.35
mmol/l
0.88
94
480
64
301
2.67
8.85
1.8
1.9
29.83
29.53
s
0.19
64
292
191
1662
5.90
7.24
25.2
14.5
36.86
24.55
mg/l
4.06
181
1324
67
351
2.38
7.17
4.7
2.0
2.47
2.43
mmol/l
1.90
60
305
16
46
3.70
5.01
3.4
1.2
59.69
46.52
mg/l
0.23
16
39
16
46
3.70
5.01
3.4
1.2
67.81
33.31
mg/l
0.72
16
40
37
173
2.40
4.96
2.4
2.9
—
—
—
0
0
124
914
1.96
4.88
4.8
3.8
0.00
0.03
estimate
0.65
32
157
121
887
1.94
4.81
4.8
3.7
0.00
0.00
estimate
-0.00
31
170
187
1635
3.83
4.69
31.1
14.1
62.63
77.22
ml/min/173m2
13.90
179
1521
12
23
5.48
4.53
1.4
1.3
—
—
—
0
0
120
903
1.84
4.14
4.9
3.7
0.00
0.00
estimate
-0.00
33
174
14
43
3.43
3.99
1.6
2.3
96.57
84.74
%
1.59
14
43
50
295
1.93
3.67
1.9
1.9
—
—
—
0
0
41
229
2.00
3.51
1.9
1.9
—
—
—
0
0
104
774
1.73
3.51
3.2
2.4
80.78
76.53
nmol/l
0.71
99
687
40
223
2.00
3.44
6.6
3.2
5.97
5.75
kpa
0.86
40
215
9
18
5.18
3.41
1.3
1.2
—
—
—
0
0
73
495
1.75
3.41
4.4
2.4
393.73
360.36
umol/l
2.25
64
429
10
23
4.52
3.36
4.1
4.1
7.36
12.95
pmol/l
—
10
23
30
152
2.15
3.32
2.9
2.1
27.79
32.43
u/l
0.87
24
122
16
60
2.81
3.32
2.3
1.2
10.28
10.79
g/l
0.14
16
51
13
43
3.17
3.32
3.5
1.2
1.79
1.31
ratio
—
8
25
99
739
1.68
3.21
5.2
4.3
13.33
9.48
mg/mmol
0.46
65
473
24
113
2.28
3.16
1.7
1.7
—
—
—
0
0
27
135
2.16
3.08
2.6
1.3
67.00
67.25
g/l
0.06
27
123
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
52
2.82
2.96
1.5
2.5
0.32
0.39
iu/ml
—
6
27
111
872
1.63
2.82
2.5
2.5
—
—
—
0
0
5
6
8.51
2.76
1.0
1.0
13.14
6.50
nmol/l
—
5
6
190
1776
2.96
2.72
16.6
11.0
25.60
26.58
u/l
0.30
185
1715
16
67
2.51
2.71
2.4
1.2
2.52
0.11
g/l
0.91
16
59
37
220
1.84
2.62
1.9
2.0
—
—
—
0
0
152
1306
1.72
2.60
5.3
4.5
15.41
12.02
mm/h
1.85
145
1207
17
75
2.39
2.59
2.3
1.2
6.79
7.35
g/l
0.66
17
66
17
75
2.39
2.59
2.3
1.2
3.95
4.15
g/l
0.44
17
66
17
75
2.39
2.59
2.3
1.2
3.01
3.72
g/l
2.26
17
66
5
7
7.29
2.56
3.2
1.4
8.74
2.71
mg/l
—
5
7
69
492
1.62
2.55
5.3
3.7
0.00
0.02
estimate
0.50
30
149
67
482
1.59
2.36
3.2
2.9
0.73
0.77
ug/l
0.20
49
320
13
53
2.56
2.33
1.9
1.2
0.00
0.00
g/l
-0.00
13
47
8
23
3.58
2.29
1.0
1.4
—
—
—
0
0
16
73
2.30
2.28
2.4
1.2
2.87
2.84
g/l
0.04
16
64
96
756
1.53
2.24
4.0
3.0
249.76
137.00
ug/l
1.27
88
702
75
569
1.51
2.04
1.8
1.7
16.77
19.95
nmol/l
1.55
66
477
84
656
1.49
1.98
4.4
3.3
2021.40
1301.17
ng/l
0.67
77
564
25
144
1.84
1.96
3.9
2.0
49.67
64.20
ml/min/173m2
1.78
15
55
183
1703
2.05
1.85
5.9
5.8
4.36
4.49
mmol/l
0.96
171
1577
13
60
2.25
1.82
2.0
1.2
0.00
0.00
g/l
-0.00
13
55
30
188
1.70
1.79
4.6
2.7
4.23
4.49
kpa
0.32
30
180
185
1735
2.09
1.72
6.8
6.7
2.51
2.60
mmol/l
0.67
171
1603
61
459
1.48
1.69
3.0
2.3
3.02
2.87
mg/l
0.20
51
396
10
43
2.40
1.61
1.5
1.5
—
—
—
0
0
52
382
1.49
1.61
1.7
1.7
1.21
1.14
mg/l
0.10
42
305
6
22
2.78
1.44
3.5
1.4
0.35
2.13
mmol/l
—
6
22
83
678
1.39
1.43
4.2
4.1
22.26
24.74
%
0.70
41
329
5
17
2.99
1.36
2.8
1.9
965.60
901.35
mg
—
5
17
10
47
2.19
1.36
1.3
1.2
—
—
—
0
0
180
1694
1.73
1.34
5.8
5.7
1.34
1.43
mmol/l
2.28
168
1556
100
849
1.36
1.33
5.9
4.4
4.16
1.93
ug/l
0.57
91
761
169
1569
1.54
1.31
6.8
5.2
2.01
1.99
mu/l
0.06
155
1426
5
18
2.82
1.29
1.8
1.1
—
—
—
0
0
24
156
1.61
1.27
1.2
1.3
—
—
—
0
0
7
31
2.30
1.11
1.1
1.3
—
—
—
0
0
7
31
2.30
1.11
1.1
1.3
—
—
—
0
0
5
21
2.42
1.09
1.2
1.0
—
—
—
0
0
15
90
1.72
1.07
2.0
1.4
—
—
—
0
0
7
33
2.16
1.06
1.1
1.2
—
—
—
0
0
176
1665
1.54
1.05
7.7
7.5
39.63
40.32
mmol/mol
0.53
167
1565
177
1678
1.54
1.03
6.5
5.6
6.11
6.09
mmol/l
0.06
166
1528
9
49
1.88
1.00
2.2
1.4
—
—
—
0
0
5
23
2.20
0.98
1.0
1.0
—
—
—
0
0
172
1632
1.42
0.87
4.9
4.8
1.36
1.29
mmol/l
0.58
158
1483
8
47
1.73
0.81
1.3
1.4
—
—
—
0
0
80
696
1.25
0.79
5.2
3.7
0.00
0.01
estimate
0.50
30
138
58
486
1.27
0.78
4.4
3.2
0.00
0.00
estimate
-0.00
30
125
9
53
1.73
0.76
1.8
1.1
—
—
—
0
0
16
108
1.52
0.76
4.2
4.2
2.15
2.54
mmol/l
0.15
11
81
36
284
1.33
0.75
1.1
1.3
26.88
16.98
u/ml
0.17
13
96
120
1098
1.24
0.73
3.4
3.4
48.77
52.18
u/l
0.19
107
1038
7
40
1.78
0.72
1.1
1.3
—
—
—
0
0
16
110
1.49
0.71
1.8
1.5
—
—
—
0
0
9
58
1.58
0.71
1.7
1.6
—
—
—
0
0
7
41
1.73
0.70
1.1
1.2
—
—
—
0
0
7
44
1.61
0.66
1.1
1.3
—
—
—
0
0
5
29
1.74
0.64
1.2
1.3
—
—
—
0
0
139
1301
1.23
0.64
5.7
3.9
15.21
14.82
pmol/l
1.18
132
1181
14
96
1.49
0.63
7.7
2.7
24.46
25.37
mmol/l
0.48
14
91
41
339
1.26
0.62
1.7
1.7
1218.56
1210.53
nmol/l
0.02
27
268
13
89
1.49
0.59
1.3
2.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.3
—
178.28
—
0
23
14
98
1.46
0.58
1.2
1.3
132.34
98.04
u/ml
—
5
36
6
35
1.74
0.58
1.0
1.5
—
—
—
0
0
6
36
1.69
0.57
1.7
1.3
—
—
—
0
0
9
60
1.52
0.55
2.0
1.7
—
—
—
0
0
20
152
1.35
0.54
4.0
2.4
0.77
0.39
e6/l
0.34
20
144
95
869
1.18
0.52
2.1
2.2
94.65
94.83
pmol/l
0.01
50
456
71
635
1.18
0.50
2.3
2.2
198.09
313.36
u/l
0.45
65
591
0
16
0.00
0.41
0.0
2.3
—
29.80
—
0
5
22
178
1.27
0.41
3.1
3.6
288.55
207.24
ng/l
0.30
22
162
5
34
1.48
0.40
1.2
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
37.03
—
0
12
0
18
0.00
0.40
0.0
1.1
—
641.92
—
0
12
11
80
1.40
0.39
1.3
1.9
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
84
776
1.14
0.38
2.4
2.0
1.46
1.35
mmol/l
0.56
71
649
82
757
1.14
0.37
4.7
3.9
107.08
83.88
ng/l
0.13
66
564
15
117
1.31
0.36
1.2
1.3
—
35.62
—
0
11
6
41
1.48
0.36
1.2
1.2
—
—
—
0
0
6
42
1.44
0.36
1.0
1.5
—
—
—
0
0
15
121
1.26
0.29
3.2
2.3
0.55
0.58
%
0.16
15
121
20
169
1.20
0.27
2.8
2.4
14.29
15.71
nmol/l
0.19
14
153
15
125
1.22
0.23
3.2
2.4
0.97
1.23
%
0.97
15
125
0
10
0.00
0.21
0.0
3.9
—
636.10
—
0
10
0
10
0.00
0.21
0.0
1.1
—
1.04
—
0
5
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
5
43
1.17
0.21
1.2
1.1
1.53
1.51
g/l
—
5
43
0
13
0.00
0.21
0.0
2.9
—
13.75
—
0
13
6
49
1.23
0.20
1.2
1.2
—
—
—
0
0
6
51
1.18
0.19
1.2
1.3
—
—
—
0
0
27
242
1.13
0.19
4.9
5.6
30.35
32.75
%
0.73
17
154
26
233
1.13
0.19
10.3
6.2
—
—
—
0
0
34
312
1.11
0.17
1.2
1.3
22.62
42.17
iu/ml
0.96
12
92
5
45
1.11
0.10
1.4
1.1
0.81
0.93
g/l
—
5
45
5
45
1.11
0.10
1.2
1.7
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
141
1390
1.05
0.08
38.9
19.7
330.75
332.58
g/l
1.54
141
1383
5
60
0.83
0.08
1.0
2.0
2.80
2.55
mg/l
—
5
47
6
74
0.80
0.07
1.2
1.3
—
—
—
0
0
45
443
1.02
0.01
5.2
3.9
1.02
1.02
kg/l
0.35
33
297
16
164
0.97
0.00
1.3
1.6
—
—
—
0
0
37
374
0.99
0.00
1.3
1.3
1.75
1.60
u/ml
—
8
95
40
404
0.99
0.00
2.1
1.7
442.69
35454954.09
pmol/l
0.50
35
330
20
197
1.02
0.00
1.7
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
8.5
—
11.17
—
0
6
0
7
0.00
0.00
0.0
3.3
—
10.23
—
0
7
0
7
0.00
0.00
0.0
1.1
—
107.44
—
0
7
0
7
0.00
0.00
0.0
1.1
—
33.96
—
0
7
0
7
0.00
0.00
0.0
3.3
—
5.43
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
11.42
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
9.46
—
0
9
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
69
1.02
-0.00
2.1
4.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_KIDNEY_CHROMOPHOBE – Chromophobe cell carcinoma of kidney
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).